358 related articles for article (PubMed ID: 29804388)
1. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
He YJ; Liu ZH; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
[TBL] [Abstract][Full Text] [Related]
2. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
Yang J; Rao HY
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
[TBL] [Abstract][Full Text] [Related]
4. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC; Baumert TF
Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
Chute DF; Chung RT; Sise ME
Kidney Int; 2018 Mar; 93(3):560-567. PubMed ID: 29325996
[TBL] [Abstract][Full Text] [Related]
6. [Research progress of hepatitis C in 2018].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):6-9. PubMed ID: 30685916
[TBL] [Abstract][Full Text] [Related]
7. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
Shah N; Pierce T; Kowdley KV
Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
[TBL] [Abstract][Full Text] [Related]
8. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
[TBL] [Abstract][Full Text] [Related]
9. Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL; Locarnini S; Beard MR
Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
11. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
Adinolfi LE; Rinaldi L; Nevola R
World J Gastroenterol; 2018 Nov; 24(41):4617-4621. PubMed ID: 30416309
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
Zhu F; Zhang QY; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
[TBL] [Abstract][Full Text] [Related]
14. [Clinical timing and benefit of antiviral treatment for hepatitis C].
Chen LC; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
[TBL] [Abstract][Full Text] [Related]
15. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
Liu X; Gao YH; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alisporivir for the treatment of hepatitis C infection.
Stanciu C; Trifan A; Muzica C; Sfarti C
Expert Opin Pharmacother; 2019 Mar; 20(4):379-384. PubMed ID: 30576256
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral agents for the treatment of HCV.
Thompson AJ; Locarnini S
Antivir Ther; 2012; 17(6 Pt B):1105-7. PubMed ID: 23188736
[No Abstract] [Full Text] [Related]
18. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
19. Are we nearing the end in the fight against hepatitis C?
Chua JV; Kottilil S
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
[No Abstract] [Full Text] [Related]
20. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
Lewis H; Cunningham M; Foster G
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
